The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Avecho (ASX:AVE) has received a US$3 million (A$4.7 million) payment from pharma heavyweight Sandoz in exchange for the ...

In a report released today, Jason Gerberry from Bank of America Securities maintained a Buy rating on Royalty Pharma (RPRX – Research Report).

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

REYOBIQ™ (rhenium Re186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM) HOUSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Plus ...

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 45th Annual Health Care Conference on ...

Blog posts represent the views of CFR fellows and staff and not those of CFR, which takes no institutional positions. Most of the major U.S. pharmaceutical companies (AbbVie, Amgen, Bristol Myers ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Could Dr. Oz use a post as head of the federal agency that oversees Medicare, Medicaid and HealthCare.gov to promote the iHerb online herbal supplements market? Sen. Elizabeth Warren, D-Mass.

Royalty Pharma plc has a 1-year low of $24.05 and a 1-year high of $34.20. Royalty Pharma ( NASDAQ:RPRX – Get Free Report ) last released its quarterly earnings results on Tuesday, February 11th.